--- title: "Weekly Recap | United Therap +2.68%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/296670781.md" description: "United Therap (UTHR) gained 2.68% this week to close at $513.12, handily outpacing the S&P 500, which slipped 1.43% — a relative outperformance of roughly 4.11 percentage points. The session charted a sharp rally followed by a pullback: the stock climbed steadily from Monday’s open of $502.29, gathered momentum on Tuesday and hit a week-high of $535.77 on Wednesday before giving back most of those gains on Thursday and Friday. The week’s amplitude reached 7." datetime: "2026-08-22T05:44:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296670781.md) - [en](https://longbridge.com/en/news/296670781.md) - [zh-HK](https://longbridge.com/zh-HK/news/296670781.md) generator: "portal-rs" --- # Weekly Recap | United Therap +2.68%, most brokers rate it buy ## The Week United Therap (UTHR) gained 2.68% this week to close at $513.12, handily outpacing the S&P 500, which slipped 1.43% — a relative outperformance of roughly 4.11 percentage points. The session charted a sharp rally followed by a pullback: the stock climbed steadily from Monday’s open of $502.29, gathered momentum on Tuesday and hit a week-high of $535.77 on Wednesday before giving back most of those gains on Thursday and Friday. The week’s amplitude reached 7.13%, while daily turnover averaged around 422,000 shares, a touch below the 60-day median. The Friday close of $513.12 sat just beneath the 20-day moving average of $519.67. ## Key Events The week’s narrative centred on a regulatory catalyst and insider selling. On Monday, the company announced it had filed for FDA priority review of a label expansion for Tyvaso in idiopathic pulmonary fibrosis (IPF) — a move that could unlock a significantly larger patient pool beyond its established pulmonary arterial hypertension franchise. Then, on Wednesday and again on Friday, Chairperson and CEO Martine Rothblatt disclosed two separate disposals of 9,500 common shares each, totalling roughly $4.79 million and $5.01 million respectively. While the transactions are modest relative to her overall holding, the timing near a key regulatory milestone drew attention. ## Analyst Ratings A total of 14 brokers cover the stock: 8 rate it a buy, 3 an overweight and 3 a hold, with no sell or underweight ratings. The consensus recommendation is buy, and the consensus target price sits at $664.33 — roughly 29.5% above the latest close. Targets range from a low of $515.00 to a high of $725.00, suggesting a fair spread of opinion on the company’s long-term value. Within the biotechnology sector, UTHR’s ranking places it at 68th out of 505 peers, comfortably inside the top 14%. ## The Week Ahead A packed macro calendar on Tuesday, 25 August, will draw attention: FHFA house price data, the Case-Shiller home price index, consumer confidence figures and new home sales are all due. These releases will offer a fresh read on the resilience of the US consumer and housing market, which could sway risk appetite for growth names in biotech. On the company front, the next real catalyst is whether the FDA grants the priority review for Tyvaso in IPF, setting the timeline for a potential label expansion. ## In Short UTHR outperformed a falling market this week, but the intra-week reversal near all-time highs reveals a tug-of-war. The bullish case rests on the Tyvaso label expansion, broad-based buy-side coverage and a P/E of roughly 16.8x that is not stretched by biotech standards. The counterpoints are the CEO’s back-to-back share disposals and the fading momentum in the back half of the week. The near-term path hinges on the FDA’s next move on the priority review filing and whether the macro data dump steadies sentiment in the growth trade. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md) ## Related News & Research - [Meiji Yasuda Asset Management Co Ltd. Makes New $5.41 Million Investment in United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/296770706.md) - [United Therapeutics says FDA accepts ralinepag NDA for pulmonary arterial hypertension](https://longbridge.com/en/news/296776376.md) - [United Therapeutics seeks FDA priority review for Tyvaso label expansion in IPF](https://longbridge.com/en/news/296094667.md) - [Amundi Sells 15,595 Shares of United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/294597709.md) - [United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares](https://longbridge.com/en/news/295639080.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**